# Eltrombopag Plus rhTPO Versus Eltrombopag for ITP During the COVID-19 Pandemic (ELABORATE-19)

> **NCT04516837** · PHASE2 · UNKNOWN · sponsor: **Peking University People's Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Immune Thrombocytopenia

## Interventions

- **DRUG:** Eltrombopag
- **DRUG:** rhTPO

## Key facts

- **NCT ID:** NCT04516837
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-31
- **Primary completion:** 2021-08
- **Final completion:** 2022-08
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2020-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04516837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04516837, "Eltrombopag Plus rhTPO Versus Eltrombopag for ITP During the COVID-19 Pandemic (ELABORATE-19)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04516837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*